{"pub_date": "2016-03-25T00:00:00Z", "subsection_name": null, "lead_paragraph": "A federal jury on Thursday ordered Gilead Sciences to pay for infringing two Merck patents related to a lucrative cure for hepatitis C.", "print_page": "2", "document_type": "article", "byline": {"person": [], "original": "By REUTERS", "organization": "REUTERS"}, "multimedia": [], "section_name": "Business Day", "headline": {"content_kicker": "Business Briefing", "print_headline": "Gilead Must Pay Merck $200 Million in Patent Dispute", "main": "Gilead Ordered to Pay Merck $200 Million in Patent Dispute"}, "source": "The New York Times", "blog": [], "word_count": "159", "web_url": "http://www.nytimes.com/2016/03/25/business/gilead-ordered-to-pay-merck-200-million-in-patent-dispute.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "A federal jury on Thursday ordered Gilead Sciences to pay for infringing two Merck patents related to a lucrative cure for hepatitis C.", "_id": "56f4a0d338f0d81726914fc4", "abstract": "San Jose, Calif, federal jury orders Gilead Sciences to pay Merck $200 million in damages for infringing Merck patents, related to lucrative hepatitis C drugs Sovaldi and Harvoni, and upholds validity of those patents. ", "keywords": [{"rank": "1", "name": "subject", "value": "Hepatitis", "is_major": "Y"}, {"rank": "2", "name": "organizations", "value": "Gilead Sciences Inc", "is_major": "Y"}, {"rank": "3", "name": "organizations", "value": "Merck & Company Inc", "is_major": "Y"}, {"rank": "4", "name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y"}, {"rank": "5", "name": "subject", "value": "Inventions and Patents", "is_major": "Y"}, {"rank": "6", "name": "subject", "value": "Harvoni (Drug)", "is_major": "N"}, {"rank": "7", "name": "subject", "value": "Sovaldi (Drug)", "is_major": "N"}]}